Vancouver-based firm, RepliCel Life Sciences Inc. has been researching the replacement of hormone-compromised hair follicle cells.
In 2013, RepliCel created a partnership with cosmetics company Shiseido, giving Shiseido an exclusive license to use its RCH-01 technology in Japan, China, South Korea, Taiwan, and the ASEAN countries. Shiseido trialed RepliCels RCH-01 in Japan and received modest results. In 2021, RepliCel initiated arbitration against Shiseido and terminated the companys license agreement.